spacer
home > white papers > Protein Therapeutics - Reading Scientific Services Ltd (RSSL)
WHITE PAPERS
logo_Reading_Scl.php

Reading Scientific Services Ltd (RSSL)

phone +44 (0)118 918 4076
email enquiries@rssl.com
web http://www.rssl.com/services/pharmaceuticalandhealthcare
email RSSL, Reading Science Centre, Whiteknights Campus, Pepper Lane, Reading, Berkshire RG6 6LA, UK

Protein Therapeutics

The use of protein-based biological materials to treat patients suffering from a wide range of diseases is one of the success stories of modern medicine. The diseases treated include diabetes (insulin), growth hormone deficiencies (recombinant human growth hormone), inborn errors of metabolism (glucosylceramidase, alpha-galactosidase), and red blood cell deficiency (erythropoietin). As the market develops, the number of biopharmaceutical products both being submitted for regulatory approval and reaching the end of their patent life is increasing.
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

3P Biopharmaceuticals receives FDA approval

[Pamplona, September 16th, 2019] 3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organisation (CDMO) specialized in process development and GMP manufacturing of biologics, receives FDA approval after completing the Pre-Approval Inspection (PAI) conducted at the 3P drug substance manufacturing facility.
More info >>


White Papers

Analysis of Biopharmaceuticals to Conform to ICHQ6B

RSSL

Worldwide, the pharmaceuticals market is anticipated to grow from more than USD 782 billion in 2011 to approach a value of just over USD 971 billion by the end of 2016, registering a CAGR of over 24%. In 2010 the average medicines expenditure per person within the UK was 271, and this is expected to increase with the ageing population. A significant and increasing proportion of these sales are protein-based biotherapeutics or biomolecules. Currently, these account for 19% of the total market, and are growing at twice the rate of traditional small molecule pharmaceuticals. It is predicted that close to 50% of the top 100 pharmaceutical products will be biomolecules by 2016. By far the largest segment of the biopharmaceutical market is the monoclonal antibody (MAb) with an estimated share of 25.6%, which corresponds to USD 51.1 billion.
More info >>


Industry Events

Evolution Summit

20-22 July 2020, The Ritz Carlton, Fort Lauderdale, FL

The 22nd Evolution Summit is the premium forum bringing leading drug development executives and solution providers together. As an invitation-only event, taking place behind closed doors, the Summit offers an intimate environment for a focused discussion of key new drivers shaping drug development.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement